Conference Reports for NATAP

The International Liver Congress™ EASL 2017 - European Association for the Study of the Liver Amsterdam, The Netherlands. 2017 Back

HCC Occurrence or Recurrence After DAA SVR at EASL 2017       from Jules: there were a bunch of studies on the subject of HCC occurrence or recurrence after DAA SVR, as this subject became of interest 2-3 years ago after several studies reported a concern, now at this meeting were a larger number of studies directly addressing the question and I added a few are also relevant.   EASL: Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/21/17)   EASL: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy - (04/24/17)   EASL: Early occurrence of hepatocellular carcinoma in patients with HCV cirrhosis treated with direct acting antivirals - (04/24/17)   EASL: Delisting of liver transplant candidates with chronic HCV infection after viral eradication and outcome after delisting. A European cohort study - (04/25/17)   EASL: Occurrence and Recurrence of Malignancies Post DAA Treatment in 5.1% of Patients- Single Center Experience - (04/26/17)   EASL: IFN-free cure of HCV infection alters the soluble inflammatory milieu in patients with liver cirrhosis which could affect HCC surveillance by CD8+ T cells - (04/26/17)   EASL: No increase in the occurrence rate of HCC in Chinese treated by DAAs compared to PR after eradication of HCV: a long-term follow-up - (04/28/17)   EASL: Direct-acting Antivirals for Hepatitis C Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence After Locoregional Therapy or Liver Transplant Waitlist Dropout - (04/26/17)   EASL: Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/26/17)   EASL: Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? - (04/26/17)   EASL: No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression - (04/26/17)   EASL: Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: Continued improvement of liver function parameters Results  from the German Hepatitis C-Registry (DHC-R) - (04/26/17)   EASL: HCV clearance after direct-acting antivirals in cirrhotic [advanced] patients by stages of liver impairment: the ITAL-C network study - (05/01/17)   EASL: Degree of Liver Fibrosis Regression Predicted by Transient Elastography after Cure of Chronic Hepatitis C with Direct Acting Antivirals is Overestimated but Confirmed by Liver Biopsy - (04/26/17)   HCV Retreatment Studies - (05/22/17)   EASL: New HCV Drugs at EASL 2017 - (05/09/17)   The International Liver Congress™ EASL 2017 - European Association for the Study of the Liver Amsterdam, The Netherlands. 2017